FGFR2 and breast carcinoma: While our in vivo data highlight the plasticity of Fgfr2-mutant HP5008 and Brca1-mutant 545 cells, further investigations using additional ERα+ cell lines are warranted to determine if this phenotypic shift is a common feature of ERα+ breast cancers.